tailieunhanh - báo cáo khoa học: "Treatment of stage I seminoma: is it time to change your practice? "

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Treatment of stage I seminoma: is it time to change your practice? | BioMed Central Journal of Hematology Oncology Open Access Editorial Treatment of stage I seminoma is it time to change your practice Darren R Feldman1 and George J Bosl 2 Address Assistant Attending Genitourinary Oncology Service Department of Medicine Memorial Sloan-Kettering Cancer Center USA and 2Chair Department of Medicine The Patrick M. Byrne Chair in Clinical Oncology Department of Medicine Memorial Sloan-Kettering Cancer Center New York NY USA Email Darren R Feldman - feldmand@ George J Bosl - boslg@ Corresponding author Published 7 November 2008 Received 21 October 2008 Journal of Hematology Oncology 2008 1 22 doi 1756-8722-1-22 Accepted 7 November 2008 This article is available from http content 1 1 22 2008 Feldman and Bosl licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract At the plenary session of the 2008 annual meeting of the American Society of Clinical Oncology updated results were presented from a large randomized phase III trial comparing adjuvant radiation therapy RT and one cycle of Carboplatin for the adjuvant treatment of Stage I seminoma. Results of this Medical Research Council MRC trial led its investigators to conclude that one cycle of carboplatin was equivalent in safety and efficacy and less toxic than RT. In this editorial the trial s design statistics toxicity and length of follow-up are discussed within the context of historical treatments of this disease. With a increase in relapse rate with carboplatin vs. with radiation a 3 or greater increase in relapse rate could not be excluded the primary endpoint of the study. A decrease in second testicular germ cell tumors was observed but was equivalent to the increase in relapse rate. .